tbuckley/cabot-search huggingface dataset:
Refining the Diagnosis of Type 2 Myocardial Infarction
Authors: Andrew R. Chapman, Nicholas L. Mills
Journal: JAMA Cardiology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Establishment and Characterization of a New Human Ph+ Erythroleukemic Cell Line, VES.
Authors: Mirna Golemovic, Lana Rnjak, Klara Dubravcic, Sanja Davidovic-Mrsic, Ivana Franic, Suncica Ries, Koraljka Gjadrov, Merica Aralica, Zdravko Mitrovic, Ranka Serventi Seiwerth, Boris Labar, Drago Batinic
Journal: Blood (2005)
GW26-e1019 Role of group I metabotropic glutamate receptors, mGluR1/mGluR5, in connexin43 phosphorylation and inhibition of gap junctional intercellular communication in H9c2 cardiomyoblast
Authors: Fei Xie, Shaolei Yi, Li Hao, Yun Zhang, Jingquan Zhong
Journal: Journal of the American College of Cardiology (2015)
Phase I trial of daily pomalidomide in patients with advanced solid tumors.
Authors: M. M. Cooney, J. A. Bokar, R. Dreicer, S. S. Krishnamurthi, P. Savvides, C. J. Nock, M. B. Rodal, L. Henderson, A. Dowlati
Journal: Journal of Clinical Oncology (2010)

e13077 Background: Pomalidomide is an IMiD analogue of thalidomide and on an equimolar basis in vitro, displays a greater stimulation of apoptosis, inhibition of COX-2 production, and inhibition of cellular TNF-alpha production relative to thalidomide. This phase I trial was undertaken to determine the maximal tolerated dose (MTD), dose-limiting toxicity (DLT), and to evaluate for any tumor response using a continuous dosing schedule. Methods: Patients with advanced solid tumors and adequate organ function were eligible. Protocol was amended to exclude ECOG patients of 2 and only allow ECOG PS of 0-1. Patients received pomalidomide once daily continuously with cycles defined as every 28 days. DLT was defined as any ≥ grade 3 nonhematologic toxicity, grade 3 transaminitis > 7 days, febrile neutropenia, grade 4 transaminitis, grade 4 neutropenia, or platelet count ≤ 25,000/ul occurring during cycle 1. Results: 24 patients, 17 male and 7 female, were enrolled but 18 were evaluable for toxicity. Fifteen different tumor types were enrolled with the most common being colon (4), pancreas (3), and 2 each of adrenal, thyroid, and NSCLC. Median age was 58 years (range 19 to 84). DLTS at the 3 mg daily dose included Grade 4 ANC, GI bleed, PE, and Grade 5 septic shock and infection. At the 4 mg daily dose DLTs included Grade 3 dehydration and Grade 4 ANC and dehydration. Protocol was amended to limit ECOG PS to 0-1 and no more than 2 prior cytotoxic regimens. Dosing was then restarted and no DLTS were observed at the 3 or 4 mg daily dosing. At the 5 mg cohort DLTs of Grade 3 leukopenia (2) and Grade 4 ANC (2) were observed. The 4 mg cohort will be expanded to include 10 patients. The median number of cycles completed is 2 (range 1 to 7). Stable disease occurred in a patient with HCC (7 cycles), NSCLC (6 cycles), and another with seminal vesicle cancer (2 cycles). Conclusions: The current dose level is 4 mg of pomalidomide continuous daily dosing. DLTs of myelosuppression, dehydration, sepsis, GI bleed, and PE have been observed. Prolonged stable disease in HCC and NSCLC were observed. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Celgene Genentech, ImClone Systems, Merck, Pfizer, sanofi-aventis, Wyeth
Influence of Stem Cell Source On GvH and NRM: Comparison of 10/10 HLA-Matched Unrelated Donor (MUD) with 9/10 HLA-Mismatched Unrelated Donor (MMUD) and Unrelated Cord Blood (UCB) Transplants.
Authors: Clémence Granier, Emeline Masson, Lucie Biard, Raphael Porcher, Regis Peffault de la Tour, Marie Robin, Alienor Xhaard, Patricia Ribaud, Pascale Loiseau, Dominique Charron, Gérard Socié, Nathalie Dhedin
Journal: Blood (2012)
Abstract A06: ‘Accidental discoveries on systematic studies: Role of inflammation in multistep tumorigenesis and angiogenesis in models of allergies
Authors: Mahin Khatami
Journal: Cancer Research (2016)

Abstract Among major scientific factors involved in extremely slow progress in cancer research and failed therapies are the lack of understanding of host tissue composition and interactions between resident immune cells and signaling for recruited cells in carcinogenesis. In 1980s experimental models of acute and chronic ocular inflammatory diseases resulted in tumorigenesis and angiogenesis. Analyses of data became accidental discoveries for systematic identification of time-course kinetics of interactions and synergies between host immune cells (e.g., mast, goblet and B cells) and recruiting cells (e.g., eosinophils and TAMs) during acute, intermediate and chronic phases of immune dynamics caused induction of tumor-like lesions in conjunctival-associated lymphoid tissues. The data are the first multiple findings on early events, followed by sequential alterations of immunity toward tissue growth and angiogenesis. In 2008, acute inflammation or effective immunity was defined as the balance between two biologically opposing arms, termed Yin (tumoricidal) and Yang (tumorigenic) properties of immune and non-immune (e.g., vasculature, neurodegenerative and metabolic) responses. Chronic inflammation was hypothesized as loss of balance in Yin and Yang and a common link for genesis of all age-associated chronic diseases or cancer. Future efforts to promote immunity should include systematic understanding of host-pathogen interactions in susceptible tissues. Outcomes are expected to hold real promise in understanding how cancer cells become threat to body and how translate cancer biology into cost-effective drug designs and clinical trials. Note: This abstract was not presented at the conference. Citation Format: Mahin Khatami, Ret. ‘Accidental discoveries on systematic studies: Role of inflammation in multistep tumorigenesis and angiogenesis in models of allergies. [abstract]. In: Proceedings of the AACR Special Conference: Function of Tumor Microenvironment in Cancer Progression; 2016 Jan 7–10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2016;76(15 Suppl):Abstract nr A06.
A 3,239 -Patient Combined Eastern Cooperative Oncology Group (ECOG), M.D. Anderson Cancer Center (MDA) Analysis of the Effect of CR vs. Responses &lt; CR on Long-Term Survival in Newly-Diagnosed AML Treated with Ara-C-Containing Regimens: Implications for Targeted Drug Development.
Authors: Elihu Estey, Zhuoxin Sun, Jacob Rowe, Stefan Faderl, Peter Cassileth, George Sartiano, Anthony Tartaglia, Guillermo Garcia-Manero, Larry Cripe, John Bennett, Hagop Kantarjian, Martin Tallman
Journal: Blood (2007)
Metastatic epitheloid hemangioendothelioma (EHE): Role of systemic therapy and survival.
Authors: A. Cioffi, A. Italiano, N. Penel, Y. Berge, M. Toulmonde, S. Salas, C. Chevreau, A. Le Cesne, F. Duffaud, D. R. D'Adamo, M. L. Keohan, C. Genebes, C. Antonescu, J. Coindre, B. Bui Nguyen, R. G. Maki
Journal: Journal of Clinical Oncology (2011)

10079 Background: Data regarding the management of patients with metastatic EHE are almost nonexistent. Methods: From 1990 to 2010, 78 adult patients (pts) with a confirmed diagnosis of EHE were referred to one of the 9 participating institutions, and their medical records reviewed. Results: Forty-two (54%) patients had metastatic disease. Median age was 45 years. Systemic therapy was delivered in 34 cases (81%): single agent in 24 cases (71%). Twenty-two patients received cytotoxic chemotherapy: anthracycline-containing regimen (+/- ifosfamide): n=16; others: n=6. Twelve patients received an angiogenesis-targeting drug and/or a tyrosine kinase inhibitor: sorafenib n=6, thalidomide: n=2, metronomic cyclophosphamide: n=2, imatinib: n=2. No objective response was observed. Fourteen patients had stable disease > 6 months: cytotoxic chemotherapy n=8 (doxorubicin-containing regimen: n=4, other n=4); angiogenesis-targeting agent n=6 (sorafenib: n=3, metronomic cyclophosphamide: n=2, thalidomide n=1). 9/16 (56%) treated with doxorubicin-containing regimen had disease progression within 3 months of starting treatment. Median progression-free survival (PFS) was 4.8 months (mo) (95% CI: 2.6-7.1). Age <45 years was the sole factor significantly associated with PFS: 6.7 mo (95% CI: 4.4-9.0) vs 2.2 mo (95% CI: 1.9-2.6) (log-rank test: p=0.03). 16 patients received further lines of systemic treatments (median: 1, range 1-4). Median overall survival (OS) was 41 mo (95% CI: 0.1-90). Age <45 years and performance status ≤1 were the sole factors significantly associated with better OS. 6/8 pts who did not receive systemic treatment are still alive, after a median of 49 months (range 11-188) from the time of distant recurrence, consistent with presence of a subset of patients with indolent disease who do not require systemic treatment. Conclusions: OS of patients with metastatic EHE appears significantly longer than most other metastatic soft-tissue tumors. Anthracyclines and ifosfamide have modest activity while long-term stable disease is achievable with anti-angiogenic drugs which have a better safety profile. Systemic therapy should be avoided in patients with indolent, asymptomatic disease.
P0969 : Role of epigenetic factors in non-alcoholic steatohepatitis development
Authors: R. Gallego-Durán, J.A. del Campo, J. Ampuero, M. García-Valdecasas, L. Rojas, H. Pastor-Ramírez, M.J. Pareja, R. Millán, M.C. Rico, A. Gil-Gómez, Á. Rojas, A. Rojas, M. Romero-Gómez
Journal: Journal of Hepatology (2015)
Social Determinants of Chronic Disease Get NIH Attention
Authors: Jennifer Abbasi
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Prospective Multivariate Analysis of Risk Factors Associated with Occurrence of Febrile Neutropenia in Any Cycle in NHL Patients Receiving Chemotherapy.
Authors: Ruth Pettengell, Andre Bosly, Thomas D. Szucs, Christian Jackisch, Robert Leonard, Robert Paridaens, Manuel Constenla, Matthias Schwenkglenks
Journal: Blood (2007)
Interim analysis of a phase II study of dose-modified FOLFIRINOX (mFOLFIRINOX) in locally advanced (LAPC) and metastatic pancreatic cancer (MPC).
Authors: Edward Samuel James, Xiaopan Yao, Xiangyu Cong, Jia Li, Carol Hahn, Kristin Kaley, Jeremy S. Kortmansky, Neal A. Fischbach, Bryan William Chang, Ronald R Salem, Charles Cha, Stacey Stein, Howard S. Hochster, Jill Lacy
Journal: Journal of Clinical Oncology (2014)

e15226 Background: Although FOLFIRINOX is superior to gemcitabine in MPC, the regimen is associated with significant toxicities (Conroy et al. N Engl J Med 2011;364:1817). In our prior retrospective analysis, efficacy was not compromised by dose attenuations of FOLFIRINOX (Gunturu et al. Med Oncol 2013;30:361). Based on this analysis, we are conducting a prospective, phase II, open-label study to evaluate the efficacy and tolerability of mFOLFIRINOX in pts with advanced pancreatic cancer (PC). Methods: Previously untreated pts with MPC or LAPC received mFOLFIRINOX with 25% dose reductions of irinotecan and bolus 5-FU given every two wks until progression, unacceptable toxicity, or surgical resection. All pts received prophylactic pegfilgrastim. FDG-PET scans were obtained at baseline and after 2 cycles. CAT scans were obtained after every 4 cycles. Toxicities and response rate (RR) were compared to historical data reported by Conroy. Results: 62 pts with ECOG PS ≤1 have been enrolled between 11/2011 and 12/2013, Pt characteristics: LAPC 27; MPC 35; median age 62 yrs (range 46-86); male 37. Median number of cycles was 8 (range 1-21). Grade 3/4 toxicities were: vomiting, peripheral sensory neuropathy (PSN) - 3.2%; ALT elevated, thromboembolism, febrile neutropenia - 4.8%; anemia - 6.4%; diarrhea, neutropenia - 16.2%; fatigue - 12.9%; thrombocytopenia - 11.3%. Neutropenia (p<0.0001) and vomiting (p=0.006) were significantly decreased. There was a nonsignificant trend toward a lower incidence of fatigue (p=0.05). Response by RECIST (CR+PR) in 29 evaluable pts with MPC was 31.4% (0 CR, 11 PR, 15 SD, 3 PD) and similar to historical data (31.6%; p 0.82). 9/21 evaluable pts with LAPC underwent resection (43%).16/43 pts evaluable for PET response had a >50% decrease in SUV(max)(37%). Conclusions: Findings from our interim analysis suggests that mFOLFIRINOX, given along with prophylactic pegfilgrastim is associated with a similar RR and improved tolerability compared to full dose FOLFIRINOX in advanced PC. In pts with LAPC, neoadjuvant FOLFIRINOX appears to have substantial activity with 43% of evaluable pts undergoing resection. Planned accrual has been completed. Interim OS and PFS will be reported. Clinical trial information: NCT01523457.
Reduced chemotherapy dose intensity in patients with ovarian cancer: Results from a prospective nationwide study
Authors: M. S. Poniewierski, J. Crawford, D. C. Dale, E. Culakova, N. M. Kuderer, D. A. Wolff, G. H. Lyman
Journal: Journal of Clinical Oncology (2008)

16508 Background: Chemotherapy represents a central component of effective multidisciplinary management of women with ovarian cancer. The study reported here was conducted to evaluate the delivery of ovarian cancer chemotherapy and the risk of treatment- associated toxicity. Methods: A prospective observational study of adult cancer patients initiating a new chemotherapy regimen was conducted at randomly selected US practice sites. Unselected patients with ovarian cancer were consented and followed over the first 4 cycles of chemotherapy. Demographic, clinical and treatment-related measures were captured at baseline and during treatment Results: Between 2002 and 2005, 312 patients with ovarian cancer were registered with mean age of 62.3 years (range: 18–89 years). 80% of patients were stages 3 or 4 with 46% reporting one or more comorbidities. Mean body mass index (BMI) was 27.5 with 30.4% classified as obese with BMI ≥ 30. Combination chemotherapy was administered to 228 (73%) patients with carboplatin-paclitaxel (47%) and carboplatin-docetaxel (10%) most frequently utilized. One-fourth of patients experienced severe or febrile neutropenia (FN) over 4 cycles of treatment. While FN was reported in only 6.6% of patients, two-thirds occurred in cycle 1. A nonstandard regimen was identified in 38 (12.2%) patients with such patients experiencing greater risk of FN (22%) than other patients (5%) (P=.001). Among the remaining 274 patients, the average relative dose intensity (RDI) over 4 cycles was 76% with 60% of patients receiving RDI <85% half of which was planned from the start of treatment. The strongest predictors of reduced RDI in multivariate analysis was the presence of obesity (P=.001), poor ECOG performance status and use of nonplatinum chemotherapy regimens. In addition, geographic residence and type of oncology practice were significant predictors of reduced RDI. Conclusions: Most patients with ovarian cancer received combination chemotherapy for locally advanced or metastatic disease. Hematologic toxicity occurred early and nearly 75% of patients received chemotherapy RDI <85% or a nonstandard regimen potentially compromising long term outcomes. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Amgen Amgen Amgen
Association Between a Prolonged PR Interval and Outcomes of Cardiac Resynchronization Therapy
Authors: Daniel J. Friedman, Haikun Bao, Erica S. Spatz, Jeptha P. Curtis, James P. Daubert, Sana M. Al-Khatib
Journal: Circulation (2016)

A prolonged PR interval is common among cardiac resynchronization therapy (CRT) candidates; however, the association between PR interval and outcomes is unclear, and the data are conflicting.We conducted inverse probability weighted analyses of 26 451 CRT-eligible (ejection fraction ≤35, QRS ≥120 ms) patients from the National Cardiovascular Data Registry ICD Registry to assess the association between a prolonged PR interval (≥230 ms), receipt of CRT with defibrillator (CRT-D) versus implantable cardioverter defibrillator (ICD), and outcomes. We first tested the association between a prolonged PR interval and outcomes among patients stratified by device type. Next, we performed a comparative effectiveness analysis of CRT-D versus ICD among patients when stratified by PR interval. Using Medicare claims data, we followed up with patients up to 5 years for incident heart failure hospitalization or death.Patients with a PR≥230 ms (15%; n=4035) were older and had more comorbidities, including coronary artery disease, atrial arrhythmias, diabetes mellitus, and chronic kidney disease. After risk adjustment, a PR≥230 ms (versus PR<230 ms) was associated with increased risk of heart failure hospitalization or death among CRT-D (hazard ratio, 1.23; 95% confidence interval, 1.14-1.31; P<0.001) but not ICD recipients (hazard ratio, 1.08; 95% confidence interval, 0.97-1.20; P=0.17) (Pinteraction=0.043). CRT-D (versus ICD) was associated with lower rates of heart failure hospitalization or death among patients with PR<230 ms (hazard ratio, 0.79; 95% confidence interval, 0.73-0.85; P<0.001) but not PR≥230 ms (hazard ratio, 1.01; 95% confidence interval, 0.87-1.17; P=0.90) (Pinteraction=0.0025).A PR≥230 ms is associated with increased rates of heart failure hospitalization or death among CRT-D patients. The real-world comparative effectiveness of CRT-D (versus ICD) is significantly less among patients with a PR≥230 ms in comparison with patients with a PR<230 ms.
68Ga-DOTATOC and 68Ga-PSMA PET/CT Unmasked a Case of Prostate Cancer With Neuroendocrine Differentiation
Authors: Sirong Chen, Shing Kee Cheung, Ka-nin Wong, Kwok Kee Wong, Chi-lai Ho
Journal: Clinical Nuclear Medicine (2016)

A bedridden 90-year-old man with fever and elevated prostate-specific antigen (PSA) (49 ng/mL) was referred for differentiation between infection and tumor. 18F-FDG PET/CT was negative for infection, but 68Ga-PSMA PET/CT showed multiple lesions in prostate gland with infiltration to bladder wall and seminal vesicle, consistent with locally advanced prostate cancer. The lesion with the highest 68Ga-PSMA uptake was strongly avid for 68Ga-DOTATOC, suggesting neuroendocrine tumor differentiation. After hormonal therapy, PSA normalized, but chromogranin-A increased (from 251 to 398 ng/mL), inferring progression of neuroendocrine tumor differentiation. Advanced prostate cancer may require investigation for pathological neuroendocrine transformation, although PSA may suggest improvement.
MicroRNA-181b Controls Atherosclerosis and Aneurysms Through Regulation of TIMP-3 and Elastin
Authors: Karina Di Gregoli, Nur Najmi Mohamad Anuar, Rosaria Bianco, Stephen J. White, Andrew C. Newby, Sarah J. George, Jason L. Johnson
Journal: Circulation Research (2016)

Rationale: Atherosclerosis and aneurysms are leading causes of mortality worldwide. MicroRNAs (miRs) are key determinants of gene and protein expression, and atypical miR expression has been associated with many cardiovascular diseases; although their contributory role to atherosclerotic plaque and abdominal aortic aneurysm stability are poorly understood. Objective: To investigate whether miR-181b regulates tissue inhibitor of metalloproteinase-3 expression and affects atherosclerosis and aneurysms. Methods and Results: Here, we demonstrate that miR-181b was overexpressed in symptomatic human atherosclerotic plaques and abdominal aortic aneurysms and correlated with decreased expression of predicted miR-181b targets, tissue inhibitor of metalloproteinase-3, and elastin. Using the well-characterized mouse atherosclerosis models of Apoe − /− and Ldlr −/− , we observed that in vivo administration of locked nucleic acid anti-miR-181b retarded both the development and the progression of atherosclerotic plaques. Systemic delivery of anti-miR-181b in angiotensin II–infused Apoe −/− and Ldlr −/− mice attenuated aneurysm formation and progression within the ascending, thoracic, and abdominal aorta. Moreover, miR-181b inhibition greatly increased elastin and collagen expression, promoting a fibrotic response and subsequent stabilization of existing plaques and aneurysms. We determined that miR-181b negatively regulates macrophage tissue inhibitor of metalloproteinase-3 expression and vascular smooth muscle cell elastin production, both important factors in maintaining atherosclerotic plaque and aneurysm stability. Validation studies in Timp3 −/− mice confirmed that the beneficial effects afforded by miR-181b inhibition are largely tissue inhibitor of metalloproteinase-3 dependent, while also revealing an additional protective effect through elevating elastin synthesis. Conclusions: Our findings suggest that the management of miR-181b and its target genes provides therapeutic potential for limiting the progression of atherosclerosis and aneurysms and protecting them from rupture.
The Use of DT388-IL3 Fusion Protein in Patients with Refractory Acute Myeloid Leukemia(AML).
Authors: Debashish Misra, Arthur Frankel, Philip Hall, Tie Fu Liu, Jennifer Black, Joseph O. Moore, Carlos de Castro, Jon P. Gockerman, Cristina Gasparetto, Mitchell Horwitz, Patricia H. Davis, Nelson J. Chao, David A. Rizzieri
Journal: Blood (2004)
Influence of the Intensity of the Conditioning Regimen on the Characteristics of Acute and Chronic Graft Versus Host Disease after Allogeneic Transplantation.
Authors: Maria Diez-Campelo, Jose A. Perez-Simon, Rodrigo Martino, Daniel Valcarce, Alvaro Urbano, Dolores M. Caballero, Angel Leon, Salut Brunet, Enric Carreras, Consuelo Maria Cañizo, Jorge Sierra, Jesus F. San Miguel
Journal: Blood (2004)